Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kyrill S Rogacev

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
Deutsche Medizinische Wochenschrift (1946)|April 3, 2020
[Lipid management 2020 - medical therapy and lipid apheresis in context]Kyrill S Rogacev, Ulrich Laufs
Nephrologie & Therapeutique|May 8, 2010
Human monocyte heterogeneity--a nephrological perspectiveKyrill S Rogacev, Gunnar H Heine
The New England Journal of Medicine|November 4, 2011
Bardoxolone methyl, chronic kidney disease, and type 2 diabetesKyrill S Rogacev, Jörg T Bittenbring, Danilo Fliser
Kidney International|March 1, 2012
CKD-associated atherosclerosis and monocyte heterogeneityKyrill S Rogacev, Adam M Zawada, Gunnar H Heine
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 21, 2013
Clinical relevance of epigenetic dysregulation in chronic kidney disease-associated cardiovascular diseaseAdam M Zawada, Kyrill S Rogacev, Gunnar H Heine
Seminars in Dialysis|June 20, 2017
Still a reasonable goal: Targeting cholesterol in dialysis and advanced chronic kidney disease patientsGunnar H Heine, Kyrill S Rogacev, Oliver Weingärtner, et al.
Hypertension (Dallas, Tex. : 1979)|December 26, 2012
Renal resistive index and cardiovascular and renal outcomes in essential hypertensionGunnar H Heine, Kyrill S Rogacev, Danilo Fliser, et al.
Pharmacology & Therapeutics|December 22, 2019
Lipid-modifying therapy in chronic kidney disease: Pathophysiological and clinical considerationsGunnar H Heine, Kathrin Eller, Julia T Stadler, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 1, 2009
Indices of systemic atherosclerosis are superior to ultrasound resistance indices for prediction of allograft survivalMarkus K Gerhart, Sarah Seiler, Oliver S Grün, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 10, 2009
Haemodialysis-induced transient CD16+ monocytopenia and cardiovascular outcomeKyrill S Rogacev, Maren Ziegelin, Christof Ulrich, et al.
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
Deutsche Medizinische Wochenschrift (1946)|April 3, 2020
[Lipid management 2020 - medical therapy and lipid apheresis in context]Kyrill S Rogacev, Ulrich Laufs
Nephrologie & Therapeutique|May 8, 2010
Human monocyte heterogeneity--a nephrological perspectiveKyrill S Rogacev, Gunnar H Heine
The New England Journal of Medicine|November 4, 2011
Bardoxolone methyl, chronic kidney disease, and type 2 diabetesKyrill S Rogacev, Jörg T Bittenbring, Danilo Fliser
Kidney International|March 1, 2012
CKD-associated atherosclerosis and monocyte heterogeneityKyrill S Rogacev, Adam M Zawada, Gunnar H Heine
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 21, 2013
Clinical relevance of epigenetic dysregulation in chronic kidney disease-associated cardiovascular diseaseAdam M Zawada, Kyrill S Rogacev, Gunnar H Heine
Seminars in Dialysis|June 20, 2017
Still a reasonable goal: Targeting cholesterol in dialysis and advanced chronic kidney disease patientsGunnar H Heine, Kyrill S Rogacev, Oliver Weingärtner, et al.
Hypertension (Dallas, Tex. : 1979)|December 26, 2012
Renal resistive index and cardiovascular and renal outcomes in essential hypertensionGunnar H Heine, Kyrill S Rogacev, Danilo Fliser, et al.
Pharmacology & Therapeutics|December 22, 2019
Lipid-modifying therapy in chronic kidney disease: Pathophysiological and clinical considerationsGunnar H Heine, Kathrin Eller, Julia T Stadler, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 1, 2009
Indices of systemic atherosclerosis are superior to ultrasound resistance indices for prediction of allograft survivalMarkus K Gerhart, Sarah Seiler, Oliver S Grün, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 10, 2009
Haemodialysis-induced transient CD16+ monocytopenia and cardiovascular outcomeKyrill S Rogacev, Maren Ziegelin, Christof Ulrich, et al.
Pageof 5